Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday. The Danish pharma giant fielded several questions from interested analysts ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN.